前列腺癌淋巴结复发中PET/CT低估肿瘤负荷:68Ga-PSMA与11C-胆碱头对头比较
本研究纳入641例根治性前列腺切除术后PSA升高且淋巴结复发、接受挽救性淋巴结清扫的患者,比较11C-胆碱(407例)与68Ga-PSMA(234例)PET/CT对肿瘤负荷的低估程度。总体11C-胆碱组低估程度显著更高(p<0.0001),多因素分析确认(p=0.028);仅在PSA≤1.5 ng/ml时68Ga-PSMA低估更低,PSA>1.5 ng/ml时两示踪剂相似。
要点
- PET/CT无论用哪种示踪剂均显著低估前列腺癌复发淋巴结负荷。
- 总体11C-胆碱组肿瘤负荷低估程度显著高于68Ga-PSMA组。
- 仅PSA≤1.5 ng/ml且淋巴结负荷有限时68Ga-PSMA低估更低。
核心结论
- PET/CT显著低估前列腺癌复发肿瘤负荷,与所用示踪剂无关。
- 68Ga-PSMA仅在PSA低于1.5 ng/ml且淋巴结肿瘤负荷有限时低估率低于11C-胆碱。
- 其他患者中68Ga-PSMA在评估淋巴结复发范围方面并不优于11C-胆碱。
研究设计与样本
- 多机构回顾性系列,纳入641例根治性前列腺切除术后PSA升高且淋巴结复发、接受挽救性淋巴结清扫的患者。
- 淋巴结复发由PET/CT记录:11C-胆碱407例(63%),68Ga-PSMA配体234例(37%)。
- 主要结局为肿瘤负荷低估,即最终病理阳性淋巴结数与PET/CT阳性spots数之差。
- 多因素分析检验示踪剂(11C-胆碱 vs 68Ga-PSMA)与肿瘤负荷低估的关联。
主要发现
- 总体11C-胆碱组肿瘤负荷低估程度显著高于68Ga-PSMA组(p<0.0001)。
- 多因素分析确认示踪剂与低估独立相关(p=0.028)。
- 按PSA分层,仅PSA≤1.5 ng/ml时68Ga-PSMA低估更低;PSA>1.5 ng/ml时两示踪剂低估相似。
- PET/CT阳性spots数越多,肿瘤负荷低估越高,与示踪剂无关(p=0.2)。
关键数值与推荐
- 总体低估程度:11C-胆碱组显著高于68Ga-PSMA组(p<0.0001)。
- 多因素分析:示踪剂与低估关联(p=0.028)。
- PSA≤1.5 ng/ml时68Ga-PSMA低估更低;PSA>1.5 ng/ml时两示踪剂相似。
- 阳性spots数越多低估越高,与示踪剂无关(p=0.2)。
临床怎么用
- 解读PET/CT淋巴结阳性结果时需警惕肿瘤负荷被低估,尤其11C-胆碱显像。
- PSA≤1.5 ng/ml且淋巴结负荷有限的患者,68Ga-PSMA可能更准确评估范围。
- PSA>1.5 ng/ml时两种示踪剂对淋巴结复发范围评估无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We compared the use of 11C-choline and 68Ga-prostate specific membrane antigen in men undergoing salvage lymph node dissection for nodal recurrent prostate cancer. MATERIALS AND METHODS: The study included 641 patients who experienced prostate specific antigen rise and nodal recurrence after radical prostatectomy and underwent salvage lymph node dissection. Lymph node recurrence was documented by positron emission tomography/computerized tomography using 11C-choline (407, 63%) or 68Ga-PSMA ligand (234, 37%). The outcome was underestimation of tumor burden (difference between number of positive nodes on final pathology and number of positive spots at positron emission tomography/computerized tomography). Multivariable analysis tested the association between positron emission tomography/computerized tomography tracer (11C-choline vs 68Ga-PSMA) and tumor burden underestimation. RESULTS: Overall the extent of tumor burden underestimation was significantly higher in the 11C-choline group compared to the 68Ga-PSMA group (p <0.0001), which was confirmed on multivariable analysis (p=0.028). Repeating these analyses according to prostate specific antigen, tumor burden underestimation was lower with 68Ga-PSMA only when prostate specific antigen was 1.5 ng/ml or less. Conversely, the underestimation of the 2 tracers became similar when prostate specific antigen was greater than 1.5 ng/ml. Furthermore, we evaluated the risk of underestimation by number of positive spots on positron emission tomography/computerized tomography. The higher the number of positive spots the higher the underestimation of tumor burden regardless of the tracer used (p=0.2). CONCLUSIONS: Positron emission tomography/computerized tomography significantly underestimates the burden of prostate cancer recurrence, regardless of the tracer used. 68Ga-PSMA was associated with a lower rate of underestimation in patients with a prostate specific antigen below 1.5 ng/ml and a limited nodal tumor load. In all other men there was no benefit from 68Ga-PSMA over 11C-choline in assessing the extent of nodal recurrence.
引用
- Fossati N, Scarcella S, Gandaglia G, et al. Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of 68Ga-PSMA and 11C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. J Urol. 2020. PMID: 32068488. doi:10.1097/JU.0000000000000800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。